4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 500% | 7.1% | 1,300% | – |
| Cost of Goods Sold | $47 | $48 | $0 | $2 |
| Gross Profit | -$47 | -$48 | $0 | -$2 |
| % Margin | -52,386.7% | -319,573.3% | 100% | -178,300% |
| R&D Expenses | $49 | $48 | $41 | $43 |
| G&A Expenses | $12 | $12 | $13 | $13 |
| SG&A Expenses | $12 | $12 | $13 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $2 |
| Other Operating Expenses | -$47 | -$48 | $0 | -$3 |
| Operating Expenses | $14 | $12 | $54 | $54 |
| Operating Income | -$61 | -$59 | -$54 | -$56 |
| % Margin | -67,983.3% | -396,373.3% | -383,007.1% | -5,611,700% |
| Other Income/Exp. Net | $4 | $5 | $6 | $6 |
| Pre-Tax Income | -$57 | -$55 | -$48 | -$50 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$57 | -$55 | -$48 | -$50 |
| % Margin | -63,195.6% | -364,386.7% | -342,657.1% | -4,967,100% |
| EPS | -1.01 | -0.98 | -0.86 | -0.9 |
| % Growth | -3.1% | -14% | 4.4% | – |
| EPS Diluted | -1.01 | -0.98 | -0.86 | -0.9 |
| Weighted Avg Shares Out | 56 | 56 | 56 | 54 |
| Weighted Avg Shares Out Dil | 56 | 56 | 56 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $5 | $6 | $6 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $2 | -$5 |
| EBITDA | -$56 | -$58 | -$52 | -$61 |
| % Margin | -61,794.4% | -388,600% | -370,478.6% | -6,103,800% |